BIOTRICITY INC by Biotricity Inc. Financials - Benzinga

BIOTRICITY INC by Biotricity Inc.

BTCYOTCQB

Trade with Public

Trade with Public

$0.4631

At close: Aug 12, 5:00 PM EST

Overview News Earnings Forecast Price TargetsFinancialsSentiment Ownership Compare

BIOTRICITY INC by Biotricity Inc. Financials

BIOTRICITY INC by Biotricity Inc. (BTCY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Biotricity Q3 EPS $(0.04) Beats $(0.08) Estimate, Sales $3.988M Miss $4.100M Estimate

Biotricity (OTC:BTCY) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.08) by 47.5 percent. This is a 740 percent decrease over losses of $(0.01) per share from the same

Benzinga Newsdesk

Earnings Preview: Biotricity

Benzinga Insights

PRO
Biotricity Q1 EPS $(0.03) Up From $(0.07) YoY, Sales $3.874M Beat $3.800M Estimate

Biotricity (OTC:BTCY) reported quarterly losses of $(0.03) per share. This is a 61.33 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $3.874

Benzinga Newsdesk

PRO
Reported Earlier, Biotricity Now Expects To Reach Milestone Of Being EBITDA Positive Before The End Of Calendar 2024

Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its accelerated timeline to achieving EBITDA positive. The

Benzinga Newsdesk

PRO
Biotricity Q4 2024 Adj EPS $(0.47) Misses $(0.36) Estimate, Sales $3.200M Inline

Biotricity (NASDAQ:BTCY) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.36) by 30.56 percent. The company reported quarterly sales of $3.200 million which met the

Benzinga Newsdesk

PRO
Biotricity Q4 Revenue $3.2M, Up 15.9% YoY, EPS $(0.47)

Benzinga Newsdesk